Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Brivekimig · SAR-442970

Other · developed by Sanofi

Phase 2 Most advanced trial
SNY Developer
2 Registered trials

What is Brivekimig?

Brivekimig (SAR442970) is administered subcutaneously.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SAR-442970
Drug type
Other
Therapy area
Gastroenterology, Renal & urology
Developer
Sanofi (SNY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
XX2BGT8CLL

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06975722 Phase 2 Ulcerative Colitis Active not recruiting SNY
NCT06500702 Phase 2 Focal Segmental Glomerulosclerosis Recruiting SNY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal LesionUlcerative Colitis

More from Sanofi

Sources

Updated Nov 22, 2026. Something wrong or missing? Report it on the SNY page.

Follow SNY, the company behind Brivekimig

See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.